HOME >> BIOLOGY >> NEWS
'Modular' leukemia drug shows promise in early testing

COLUMBUS , Ohio -- A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

Our findings have significant implications for the treatment of CLL and related malignancies, says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires en
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
28-Jun-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Researchers discover inherited mutation for leukemia
4. Inherited genes linked to toxicity of leukemia therapy
5. Unstable leukemia stem cells may predispose patients to drug resistance
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... 2020 , ... Aesthetics Biomedical (ABM), a leading aesthetics product ... only the products and treatments developed, but also the dedicated team behind the ... brands built by ABM have received several honors already for 2020, each of ...
(Date:7/1/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... on building awareness and solutions for glioblastoma—the most common and aggressive adult brain ... Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... antibody development services, today announced that the company has received ISO9001:2015 certification ... pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... 2020 , ... Diversified Technologies, Inc. has introduced a full ... drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter Systems ... push-pull configuration; yielding fast fall time for a capacitive load. These all solid-state ...
(Date:7/31/2020)... TORONTO (PRWEB) , ... July 29, 2020 , ... eSource ... and inefficiencies. This webinar will cover the history of eSource, the reasons it did ... From EMR/EHR to wearables, to site source, the industry is moving towards capturing data ...
Breaking Biology Technology:
Cached News: